Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Stephan

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
Brain Communications|January 12, 2023
Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4Marloes Stam, Camiel A Wijngaarde, Bart Bartels, et al.
European Journal of Neurology|October 10, 2023
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndromePieter A van Doorn, Peter Y K Van den Bergh, Robert D M Hadden, et al.
European Journal of Neurology|September 5, 2024
Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseasesKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Neurology. Clinical Practice|April 12, 2021
Facial Onset Sensory and Motor Neuronopathy: New Cases, Cognitive Changes, and PathophysiologyEva M J de Boer, Andrew W Barritt, Marwa Elamin, et al.
Brain Communications|September 21, 2020
<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalizationGijs H P Tazelaar, Steven Boeynaems, Mathias De Decker, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Brain Communications|January 12, 2023
Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4Marloes Stam, Camiel A Wijngaarde, Bart Bartels, et al.
European Journal of Neurology|October 10, 2023
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndromePieter A van Doorn, Peter Y K Van den Bergh, Robert D M Hadden, et al.
European Journal of Neurology|September 5, 2024
Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseasesKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Neurology. Clinical Practice|April 12, 2021
Facial Onset Sensory and Motor Neuronopathy: New Cases, Cognitive Changes, and PathophysiologyEva M J de Boer, Andrew W Barritt, Marwa Elamin, et al.
Brain Communications|September 21, 2020
<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalizationGijs H P Tazelaar, Steven Boeynaems, Mathias De Decker, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
Pageof 23